A share price of Climb Bio Inc [CLYM] is currently trading at $2.19, down -2.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The CLYM shares have gain 27.33% over the last week, with a monthly amount glided 47.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Climb Bio Inc [NASDAQ: CLYM] stock has seen the most recent analyst activity on August 15, 2025, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $9. Previously, Oppenheimer started tracking the stock with Outperform rating on June 06, 2025, and set its price target to $10. On May 22, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $7 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $10 on December 02, 2024.
Climb Bio Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $8.79. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $2.19 at the most recent close of the market.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.23 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.13 points at the first support level, and at 2.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.26, and for the 2nd resistance point, it is at 2.34.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Climb Bio Inc [NASDAQ:CLYM] is 14.08. On the other hand, the Quick Ratio is 14.08, and the Cash Ratio is 3.66.
Transactions by insiders
Recent insider trading involved Brennan Aoife, President and CEO, that happened on Jun 30 ’25 when 20618.0 shares were sold. SVP, Finance & CAO, Pimblett Emily completed a deal on Jun 20 ’25 to sell 1242.0 shares. Meanwhile, SVP, Finance & CAO Pimblett Emily sold 1199.0 shares on Mar 20 ’25.
